Alpha Cognition Inc
ACOG
Clasificación en acciones
#20038
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Precio por acción
$8.75
Capitalización bursátil
$135.82M
Cambio (1 día)
2.88%
Cambio (1 año)
73.86%
País
US
Comercio Alpha Cognition Inc (ACOG)
Categoría
Healthcare
Ratio P/B de Alpha Cognition Inc (ACOG)
Ratio P/B al October 2026 TTM: -114.63
Según los informes financieros más recientes y el precio de las acciones de Alpha Cognition Inc, el ratio P/B actual (TTM) es -114.63. Al final de 2022, el ratio P/B era -274.94.
Historial del ratio P/B de Alpha Cognition Inc desde 2018 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | -114.63 | -53.90% |
| 2023 | -248.67 | -9.55% |
| 2022 | -274.94 | -288.08% |
| 2021 | 146.19 | -97.93% |
| 2020 | 7.05K | 6,164.26% |
| 2019 | 112.47 | 16.25% |
| 2018 | 96.75 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -105.45% |
US
|
|
| 13.2547 | -111.56% |
US
|
|
| 4.208 | -103.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -105.39% |
NL
|
